Immunocore Holdings plc - ADR Aktie News

Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026 PR...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline.

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected hepatocytes (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 160 mcg selected as the go-forward dose for brenetafusp in Phase 3 PRISM-MEL-301 trial, following Independent Data Monitoring Committee review Cash...

Many stocks are objectively overvalued. That can make it difficult for investors to find opportunities for stocks with the potential to double.